(Q84582638)
Statements
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial (English)
H C Diener
D W Dodick
S K Aurora
C C Turkel
R E DeGryse
R B Lipton
S D Silberstein
M F Brin
PREEMPT 2 Chronic Migraine Study Group